Trial Profile
A phase I study of a second generation clusterin antisense oligonucleotide (OGX-011) in combination with docetaxel
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Custirsen (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- 21 Sep 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 10 Feb 2006 New trial record.